evipedia.ai
← Back

Hyperbaric Oxygen Therapy for Health & Longevity

Evidence Review created on 10/24/2026 using AI4L / Opus 5.5

Also known as: HBOT, HBO, HBO2, Hyperbaric Oxygen, Hyperbaric Oxygenation, Hyperbaric Oxygen Treatment

Motivation

Hyperbaric oxygen therapy (HBOT) means breathing pure oxygen inside a pressurized chamber, usually at about twice normal air pressure. The added pressure forces far more oxygen to dissolve in the blood than ordinary breathing can, and repeated sessions are thought to switch on repair signals in tissues. Long established in hospital medicine, it is now also offered by private clinics as a way to slow aspects of aging.

Interest among health-focused adults grew after an Israeli research program began testing intensive courses in healthy older people, measuring brain function and exercise capacity. The courses are demanding: dozens of near-daily sessions lasting about two hours, spread over several months, usually paid for privately, with a commercial clinic network built around the protocol.

This review examines the evidence on hyperbaric oxygen therapy for health and longevity: what it may do for thinking and physical capacity, how strong and independent that evidence is, what risks the pressure and the oxygen carry, and what a typical course involves in practice.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and narrative reviews that give a high-level overview of hyperbaric oxygen therapy for aging.

Note on priority experts: Only four items are listed because no further in-depth, publicly available overview qualified. Andrew Huberman, Chris Kresser and Life Extension Magazine mention hyperbaric oxygen only in passing; Life Extension covers the Shamir telomere study in one section of a broad 2022 age-reversal conference summary. Rhonda Patrick’s in-depth discussions (Q&A #18, #42, #60) are members-only, and her public Science Digest story is a brief single-study summary.

Grokipedia

Hyperbaric medicine

An encyclopedia-style overview of clinical hyperbaric medicine that distinguishes hard-shell clinical chambers at 2.0–3.0 atmospheres from soft “mild” chambers at 1.3–1.5 atmospheres.

Examine

No Examine article on hyperbaric oxygen therapy exists. Examine.com covers supplements and nutrition; its site search returns only two short members-only research-feed summaries (telomere length, skin aging), not a dedicated page.

ConsumerLab

No ConsumerLab article on hyperbaric oxygen therapy exists. ConsumerLab.com tests supplements and consumer health products; its search returns the term only inside unrelated reports on colloidal silver and Pycnogenol.

Systematic Reviews

This section lists systematic reviews and meta-analyses covering hyperbaric oxygen in older adults, longevity uses, established indications and its principal risk.

Mechanism of Action

  • Dissolved oxygen: At 2–3 atmospheres absolute (ATA, multiples of sea-level pressure), breathing 100% oxygen dissolves more than ten times the usual amount of oxygen in plasma (Henry’s law: gas dissolves in proportion to its pressure), supplying tissues where blood flow or hemoglobin is limited.
  • Hyperoxic-hypoxic paradox: The Shamir Medical Center group proposes that repeated swings between high and normal oxygen are sensed as relative oxygen shortage, activating HIF-1α (hypoxia-inducible factor 1-alpha, a master switch for low-oxygen genes), new blood vessel growth, stem cell release and mitochondrial biogenesis (building new cellular power plants) (Hadanny & Efrati, 2020).
  • Stem cell mobilization: In humans, one 2-ATA session doubled circulating CD34+ progenitor cells (bone-marrow cells that help build blood vessels) and 20 sessions raised them eightfold; mouse work implicated nitric oxide (Thom et al., 2006).
  • Inflammation and repair: A systematic review of human studies found that session-induced oxidative stress lowers pro-inflammatory proteins and raises growth factors, possibly via NF-κB (nuclear factor kappa B, a central inflammation switch), though often only briefly after each session (De Wolde et al., 2021).
  • Pressure effects: Pressure shrinks gas bubbles, explaining its role in diving accidents.
  • Competing view: The same reactive oxygen species (ROS, unstable molecules that damage cells) underlie oxygen toxicity, and the paradox hypothesis rests largely on one group’s data.
  • Pharmacology: Oxygen is not metabolized by liver enzymes and has no drug-like half-life; tissue oxygen falls back toward baseline within hours of decompression, so lasting effects require repeated sessions.

Historical Context & Evolution

Pressurized chambers were first used therapeutically centuries ago with compressed air, without strong evidence. Hyperbaric oxygen entered modern medicine around 1960, when Dutch surgeon Ite Boerema’s group reported “Life without blood”: experimental animals kept alive largely by oxygen dissolved under pressure (Boerema et al., 1960). The original intended uses were cardiac surgery, gas gangrene (gas-producing muscle infection) and, especially, diving accidents such as decompression sickness (gas bubbles forming in tissues after a dive), later extended to carbon monoxide poisoning, non-healing wounds and radiation injury.

Professional bodies then codified indications. A 2017 European consensus separated accepted from non-accepted indications (Mathieu et al., 2017); its member physicians derive revenue from delivering the treatments it endorses.

Interest in health optimization grew after the Shamir group reported late recovery after stroke (Efrati et al., 2013) and concussion (Boussi-Gross et al., 2013), then in 2020 reported better cognition, longer immune-cell telomeres and fewer senescent (aged, non-dividing) cells in healthy older adults (Hadanny et al., 2020; Hachmo et al., 2020). In parallel, a US military sham-controlled trial found that chamber sessions without extra oxygen produced similar symptom gains in concussion (Miller et al., 2015), and commentators noted that the telomere study had no control group (FoundMyFitness digest).

What changed was the target population (healthy aging adults rather than patients) and the protocol (long, intermittent courses at 2 atmospheres aimed at regeneration). Neither side’s position is settled: positive findings come mainly from one group, while sham-controlled tests remain few.

Expected Benefits

High 🟩 🟩 🟩

Hearing Recovery After Sudden Hearing Loss ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Added to medical therapy, hyperbaric oxygen improved hearing after sudden sensorineural hearing loss (abrupt inner-ear or nerve deafness) in randomized controlled trials (RCTs) from independent groups led by Topuz in Turkey and Tong in China, and in a meta-analysis of 10 randomized and non-randomized studies by Alter et al.. A Korean RCT by Cho found higher recovery rates but no difference in average hearing thresholds. This bears on recovery from an acute ear event, not on aging. Net: pooled trials favor a meaningful add-on benefit when started early.

Magnitude: Odds ratio (OR, how much more likely an outcome is in one group) for hearing recovery 2.61 (95% confidence interval [CI, the range likely to contain the true value] 1.86–3.68) versus medical therapy alone (Alter et al., 2026); mean hearing gain 10.3 decibels more than control (95% CI 6.5–14.1) (Joshua et al., 2022).

Diabetic Foot and Venous Leg Ulcer Healing ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Added to wound care, hyperbaric oxygen improved healing of chronic diabetic foot ulcers in a double-blind RCT by Löndahl in Sweden and in meta-analyses by Kranke (Cochrane) and Monami, the latter also finding fewer major amputations; for venous leg ulcers (chronic wounds from poor vein return), a meta-analysis by Bai found faster healing only alongside surgery. RCTs by Fedorko in Canada and Santema in the Netherlands found no diabetic healing or limb-salvage benefit. This bears on wound healing, not aging. Net: pooled data favor faster healing; durable benefit is uncertain.

Magnitude: Diabetic ulcers healed at six weeks: risk ratio (RR, the ratio of event rates between groups) 2.35 (95% CI 1.19–4.62) versus no hyperbaric oxygen, with no significant difference at one year (Kranke et al., 2015); healed at one year 52% with hyperbaric oxygen versus 29% with hyperbaric air (Löndahl et al., 2010); venous ulcer healing time weighted mean difference (average gap between groups, weighted by study size) −13.76 (95% CI −20.42 to −7.10) versus surgery alone, unit not stated in the abstract (Bai et al., 2023).

Late Radiation Tissue Injury ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

For tissue damage appearing months or years after radiotherapy, a Cochrane review by Lin found low-certainty improvement across head, neck, bladder and rectal injuries, and the Nordic RICH-ART trial led by Oscarsson improved symptoms of radiation cystitis (bladder inflammation). The UK sham-controlled HOT2 trial by Glover found no bowel benefit, and the HOPON trial by Shaw found no prevention of osteoradionecrosis (jaw-bone death). This bears on cancer survivorship, not aging. Net: benefit appears site-specific, clearer for bladder than bowel or jaw.

Magnitude: Complete resolution or significant improvement RR 1.39 (95% CI 1.02–1.89) versus no hyperbaric oxygen (Lin et al., 2023); urinary symptom score improved 10.1 points more than standard care (95% CI 2.2–18.1) on the Expanded Prostate Index Composite (Oscarsson et al., 2019).

Cognitive Function in Older Adults ⚠️ Conflicted

In an RCT of 63 healthy adults over 64 by Hadanny (Shamir group, Israel; authors lead commercial Aviv Scientific), 60 sessions improved global cognition versus no-treatment control. A meta-analysis by Lin et al. of 11 RCTs found better Mini-Mental State Examination (MMSE, a 30-point cognitive screen) scores in Alzheimer’s disease. However, the only sham-controlled trial, in 155 older adults with type 2 diabetes (NCT03036254), posted similar gains in both arms. Net: unblinded trials favor modest gains, but expectation effects remain unresolved.

Magnitude: Global cognition improved versus control (group-by-time interaction, the difference in change between groups, p = 0.0017; p-value, how likely such a result is by chance alone), with net effect sizes (standardized differences versus control) of 0.745 for attention and 0.788 for processing speed (Hadanny et al., 2020); MMSE 3.08 points higher than control (95% CI 2.56–3.61) (Lin et al., 2024); sham trial composite z-score (score in standard-deviation units) at 12 weeks 0.18 with hyperbaric oxygen versus 0.32 with sham, from baselines of −0.012 and 0.021, not compared between groups (NCT03036254).

Medium 🟩 🟩

Aerobic Capacity and Physical Performance

In sedentary adults over 64, an RCT by Hadanny (registered as NCT02790541) found that 60 sessions raised VO₂max (maximal oxygen uptake, the peak rate the body can use oxygen) and heart-muscle blood flow versus no-treatment control. A double-blind, sham-controlled RCT in 37 middle-aged master athletes by the same Shamir group (Hadanny et al., 2022) found higher VO₂max and mitochondrial respiration (cellular energy production). No independent group has replicated these findings.

Magnitude: Older adults: VO₂max per kilogram rose 1.91 mL/kg/min in the hyperbaric group, net effect size 0.455 versus control (p = 0.0034) (Hadanny et al., 2024); athletes: VO₂max effect size 0.989 versus sham (p = 0.010) (Hadanny et al., 2022).

Depressive and Post-Traumatic Stress Symptoms ⭕️ Not Central to Health & Longevity

A meta-analysis by Al-Shamali et al. of nine RCTs found fewer depressive symptoms with hyperbaric oxygen at 2 atmospheres but not at 1.2, with results varying widely between trials. In a sham-controlled RCT of 63 veterans with combat-related post-traumatic stress disorder (PTSD), 60 sessions delivered by the Shamir group (Doenyas-Barak et al., 2024) reduced symptoms on the Clinician-Administered PTSD Scale (CAPS-5, a structured interview scale), while sham scores rose. No independent group has run a comparable PTSD trial. This bears on mental health, not aging.

Magnitude: Depressive symptoms: Cohen’s d (a standardized effect size) −0.82 versus control overall and −0.68 versus sham (Al-Shamali et al., 2026); CAPS-5 total fell from 42.6 to 25.8 with hyperbaric oxygen and rose from 45.1 to 47.8 with sham, not compared between groups in the abstract (Doenyas-Barak et al., 2024).

Long COVID Symptoms ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In a sham-controlled RCT of 73 patients, 40 sessions delivered by the Shamir group (Zilberman-Itskovich et al., 2022) improved global cognition, energy, sleep and pain. The Swedish sham-controlled HOT-LoCO trial by Kjellberg found no benefit of 10 sessions on physical function at 13 weeks, with both arms improving. This bears on post-viral recovery, not aging. Net: any benefit may require many more sessions and remains unconfirmed outside one group.

Magnitude: Global cognition effect size 0.495 versus sham (p = 0.038) (Zilberman-Itskovich et al., 2022); physical-function difference 0.63 points versus placebo (95% CI −7.04 to 8.29) (Kjellberg et al., 2025).

Fibromyalgia Pain ⭕️ Not Central to Health & Longevity

In a review by Chen et al. of nine studies (288 patients) of hyperbaric oxygen in fibromyalgia (chronic widespread pain syndrome), a meta-analysis of the three randomized trials found less pain; most studies also described fewer tender points and less fatigue, without pooling. None of the three trials was blinded, and adverse events occurred in 23.8% of treated patients. This bears on chronic pain, not aging.

Magnitude: Pain standardized mean difference (SMD, effect expressed in standard-deviation units) −1.56 (95% CI −2.18 to −0.93) versus control, pooled from three randomized trials (Chen et al., 2023).

Acute Migraine Relief ⭕️ Not Central to Health & Longevity

For acute migraine attacks (recurrent severe headaches), a Cochrane review by Bennett pooled three small sham-controlled crossover trials (each participant received both treatments in turn) and found that hyperbaric oxygen relieved attacks more often than sham. The evidence was rated low quality, and the review found no evidence that sessions prevent future attacks or reduce rescue medication. This bears on headache treatment, not aging.

Magnitude: Migraine relief risk ratio 6.21 (95% CI 2.41–16.00) versus sham, pooled from three trials with 58 participants, low-quality evidence (Bennett et al., 2015).

Survival After Acute Coronary Syndrome ⭕️ Not Central to Health & Longevity

Added to standard care for heart attack or unstable angina (acute coronary syndrome, a sudden loss of blood flow to heart muscle), hyperbaric oxygen was associated with fewer deaths in a Cochrane review by Bennett of six small randomized trials (665 patients). The trials were small, poorly reported and at risk of bias, and the authors judge routine use unjustified. This bears on emergency heart care, not aging.

Magnitude: Death RR 0.58 (95% CI 0.36–0.92) versus no hyperbaric oxygen, low-quality evidence (Bennett et al., 2015).

Survival After Traumatic Brain Injury ⭕️ Not Central to Health & Longevity

Added to intensive care after traumatic brain injury, hyperbaric oxygen reduced deaths and improved coma scores in a Cochrane review by Bennett of seven small unblinded randomized trials (571 patients), with little evidence that survivors recovered well. In two trials, serious lung complications affected 13% of treated patients versus none of controls. This bears on acute brain-injury care, not aging.

Magnitude: Death RR 0.69 (95% CI 0.54–0.88) versus no hyperbaric oxygen, with a number needed to treat (NNT, patients treated to prevent one death) of 7 as reported by the review (Bennett et al., 2012).

Necrotizing Soft-Tissue Infection Survival, Including Gas Gangrene ⭕️ Not Central to Health & Longevity

For necrotizing soft-tissue infection (flesh-destroying infection), including gas gangrene (clostridial myonecrosis, a muscle infection by gas-producing bacteria), both covered by Medicare (Medicare coverage determination), a meta-analysis by Huang of retrospective studies (49,152 patients) linked hyperbaric oxygen to lower mortality and less multiple organ failure, though more surgical wound cleanings; its authors rate the evidence weak because no study was randomized. A Finnish gas gangrene series by Korhonen reported 22.6% mortality without a control group. This bears on acute infection care, not aging.

Magnitude: Mortality RR 0.522 (95% CI 0.403–0.677) versus no hyperbaric oxygen in retrospective studies (Huang et al., 2023); gas gangrene mortality 22.6% (12 of 53 patients) with hyperbaric oxygen added to surgery and antibiotics, no control group (Korhonen et al., 1999).

Skin Flap and Graft Survival ⭕️ Not Central to Health & Longevity

For surgically transferred skin flaps and for compromised skin grafts, the latter covered by Medicare (Medicare coverage determination), a meta-analysis by He of 13 RCTs (1,226 patients) found better flap survival, higher flap oxygen saturation and faster resolution of swelling; clinical lists also include burn grafts (Mayo Clinic overview). The abstract does not grade certainty or describe blinding. This bears on surgical recovery, not aging.

Magnitude: Skin-flap survival OR 8.57 (95% CI 5.54–13.26) versus no hyperbaric oxygen (He et al., 2026).

Wound Infection After Severe Limb Injury ⭕️ Not Central to Health & Longevity

After severe traumatic limb injuries, including crush injuries that Medicare covers (Medicare coverage determination), a meta-analysis by Choi of three RCTs and four observational studies found fewer wound infections and less tissue death with hyperbaric oxygen, but no faster healing or shorter hospital stay. Certainty was low to very low. This bears on trauma care, not aging.

Magnitude: Wound infection OR 0.31 (95% CI 0.22–0.45) versus no hyperbaric oxygen, low-certainty evidence (Choi et al., 2026).

Vision After Retinal Artery Occlusion ⭕️ Not Central to Health & Longevity

For retinal artery occlusion (sudden blockage of the artery supplying the retina), a meta-analysis by Elfil of nine comparison studies (499 patients) found better best-corrected visual acuity (sharpness of vision with glasses or lenses) with hyperbaric oxygen, plus fewer cases of neovascular glaucoma (abnormal vessel growth raising eye pressure) and stroke. The studies were small, varied and non-randomized. This bears on an acute eye emergency, not aging.

Magnitude: Best-corrected visual acuity mean difference (average gap between groups) −0.63 (95% CI −1.14 to −0.12) versus no hyperbaric oxygen after sensitivity analysis (a re-analysis checking whether the result holds when studies are excluded), with lower values indicating better vision (Elfil et al., 2026).

Parkinson’s Disease Sleep and Non-Motor Symptoms ⭕️ Not Central to Health & Longevity

In Parkinson’s disease, a meta-analysis by Tan et al. of seven RCTs (461 patients) found that adding hyperbaric oxygen to standard treatment improved sleep efficiency, sleep quality and daytime sleepiness. A broader review by Pan et al. of 16 randomized and before-after studies, from the same Chinese research group, reported gains in anxiety, depression and cognition, partly against baseline rather than controls. This bears on Parkinson’s disease symptoms, not aging.

Magnitude: Pittsburgh Sleep Quality Index 2.52 points lower (better) than control (95% CI 2.18–2.85) and sleep efficiency 15.26 points higher (95% CI 10.89–19.63) (Tan et al., 2024).

Spinal Cord Injury Recovery ⭕️ Not Central to Health & Longevity

Added to conventional treatment after traumatic incomplete spinal cord injury (partial trauma damage to the spinal cord), hyperbaric oxygen improved motor function, sensation and daily-living independence in a meta-analysis by Shi et al. of 15 RCTs. The authors note methodological limitations and possible publication bias (selective publication of positive results). This bears on recovery from spinal trauma, not aging.

Magnitude: American Spinal Injury Association (ASIA, a standard neurological examination scale) motor score 10.30 points higher than conventional treatment alone (95% CI 7.70–12.90) (Shi et al., 2026).

Tumor Control With Radiotherapy ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Breathing hyperbaric oxygen during radiotherapy may make low-oxygen tumor tissue more sensitive to radiation. A Cochrane review by Bennett of 19 trials found fewer deaths and local recurrences in head and neck cancer, possibly only with unusual radiation schedules, but no benefit in cervical or bladder cancer. In glioma (a primary brain tumor) given chemoradiotherapy (combined chemotherapy and radiotherapy), a meta-analysis of nine RCTs by Cui reported higher response rates and 3-year survival. This bears on cancer treatment, not aging. Net: benefit appears site-specific, clearest in head and neck cancer.

Magnitude: Head and neck cancer death at one year RR 0.83 (95% CI 0.70–0.98) versus radiotherapy without hyperbaric oxygen, number needed to treat 11 as reported by the review (Bennett et al., 2018); glioma objective tumor response OR 3.67 (95% CI 2.59–5.18) versus chemoradiotherapy alone (Cui et al., 2026).

Male Fertility ⭕️ Not Central to Health & Longevity

Added to conventional treatment of male infertility, hyperbaric oxygen improved sperm density, motility (swimming ability), morphology (normal shape) and survival and raised clinical pregnancy rates in a meta-analysis by Liu et al. of nine RCTs. The authors note the small number of trials and possible publication bias. This bears on reproductive health, not aging.

Magnitude: Sperm parameters and clinical pregnancy rate improved versus conventional treatment alone; the abstract and results text report no pooled outcome figure (Liu et al., 2025).

Diabetic Peripheral Neuropathy ⭕️ Not Central to Health & Longevity

Added to standard therapy for diabetic peripheral neuropathy (diabetes-related nerve damage causing numbness or pain in the limbs), hyperbaric oxygen raised the treatment response rate and nerve conduction speed in a meta-analysis by Weng et al. of 14 RCTs (1,323 patients). None of the trials was double-blind, and the authors found publication bias in several outcomes. This bears on diabetes complications, not aging.

Magnitude: Median-nerve motor conduction velocity 5.53 m/s faster than standard therapy alone (95% CI 4.13–6.93) (Weng et al., 2024).

Femoral Head Necrosis ⭕️ Not Central to Health & Longevity

For femoral head necrosis (death of bone at the top of the thigh bone after loss of blood supply), a meta-analysis by Li et al. of nine controlled studies (623 patients) found more clinical improvement with hyperbaric oxygen than with control treatment, in both Asian and non-Asian subgroups. The abstract does not grade certainty or report how many studies were randomized. This bears on bone and joint disease, not aging.

Magnitude: Clinical improvement OR 4.95 (95% CI 3.24–7.55) versus control (Li et al., 2017).

Pathological Scar Recurrence ⭕️ Not Central to Health & Longevity

For keloids and hypertrophic scars (raised, overgrown scars), a meta-analysis by Xie et al. of four comparative studies (one randomized, one non-randomized controlled, two retrospective cohorts) found fewer recurrences after surgery and radiotherapy with hyperbaric oxygen. The evidence base is small. This bears on scar management, not aging.

Magnitude: Scar recurrence OR 0.26 (95% CI 0.13–0.52) versus no hyperbaric oxygen (Xie et al., 2023).

Brain Abscess Outcomes ⭕️ Not Central to Health & Longevity

For brain abscess (a walled-off pocket of pus in the brain), a Swedish population-based comparative cohort by Bartek of 40 surgically treated adults found fewer reoperations, fewer recurrences and more good long-term outcomes when hyperbaric oxygen was added to surgery and antibiotics. The study was small, retrospective and non-randomized; clinical lists include brain abscess among uses (Mayo Clinic overview). This bears on acute brain infection care, not aging.

Magnitude: Reoperation in 10% with hyperbaric oxygen versus 45% without, and good outcome (Glasgow Outcome Score of 5, a recovery scale where 5 means good recovery) in 80% versus 45% (Bartek et al., 2016).

Autism Symptoms in Children ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In children and adolescents with autism spectrum disorder (a developmental condition affecting social communication and behavior), a meta-analysis by Tu et al. of 17 randomized and quasi-experimental (non-randomized intervention) studies (890 patients) found fewer core symptoms, though the authors rate study quality as poor. A double-blind Thai RCT by Sampanthavivat found equal improvement with sham air, and a Cochrane review by Xiong found no evidence of benefit. This bears on childhood development, not aging. Net: pooled gains rest on weak studies and were not seen against sham.

Magnitude: Core autism symptoms standardized mean difference −0.66 (95% CI −1.04 to −0.28) versus control (Tu et al., 2025).

Acute COVID-19 Hypoxemia ⭕️ Not Central to Health & Longevity

For severe COVID-19 pneumonia with hypoxemia (low blood oxygen), an unblinded RCT by Cannellotto in Argentina corrected hypoxemia faster than standard care but did not reduce mechanical ventilation or deaths; the trial stopped early at 40 patients. A living systematic review by Boet found improved outcomes in eight studies, two randomized, without pooling them. This bears on acute infection care, not aging.

Magnitude: Median time to correct hypoxemia 3 days with hyperbaric oxygen versus 9 days with standard care; recovery from hypoxemia by day 3 OR 23.2 (95% CI 1.6–329.6) versus standard care (Cannellotto et al., 2022).

Low 🟩

Post-Concussion Symptoms ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Unblinded RCTs by Boussi-Gross (Israel) and Harch (USA) reported cognitive and symptom gains, but the military sham-controlled trial by Miller found equal improvement with sham pressurization. This bears on brain-injury recovery, not aging. Net: gains may reflect non-oxygen effects of chamber sessions.

Magnitude: Symptom-score improvement 5.4 points with hyperbaric oxygen versus 7.0 with sham, with no difference between them (p = 0.70) (Miller et al., 2015).

Carbon Monoxide Poisoning Outcomes ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A double-blind RCT by Weaver reduced cognitive after-effects of poisoning, but a Cochrane review by Buckley of six RCTs found no significant pooled benefit; it notes both positive trials stopped early and negative trials were underpowered. This bears on emergency poisoning care. Net: prevention of lasting brain effects remains uncertain.

Magnitude: Cognitive after-effects at six weeks 25.0% versus 46.1% with normal-pressure oxygen (Weaver et al., 2002); pooled neurological deficits OR 0.78 (95% CI 0.54–1.12) (Buckley et al., 2011).

Stroke Recovery ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A crossover RCT by Efrati reported neurological gains 6–36 months after stroke, but a meta-analysis of acute-stroke RCTs by Li et al. found no effect on stroke severity. This bears on stroke rehabilitation. Net: chronic-stroke benefit rests on one group, and acute benefit is unsupported.

Magnitude: Acute stroke: National Institutes of Health Stroke Scale difference −1.41 points (95% CI −7.41 to 4.58) versus control (Li et al., 2024).

Cerebral Palsy Motor Function ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In children with cerebral palsy (a movement disorder from early brain injury), a meta-analysis by Zhang of 25 RCTs reported better motor and developmental scores. A systematic review by Laureau found similar gains in control groups, mostly pressurized air. This bears on childhood disability. Net: higher-quality trials show no benefit.

Magnitude: Gross Motor Function Measure standardized mean difference 0.29 (95% CI 0.07–0.51) versus control, very-low-certainty evidence (Zhang et al., 2022); higher-quality RCTs found similar improvement in both groups (Laureau et al., 2022).

Exercise Recovery ⚠️ Conflicted

A meta-analysis by Luo et al. of 10 RCTs found faster normalization of muscle-injury blood markers after strenuous exercise but no reduction in muscle soreness. Net: little noticeable recovery benefit.

Magnitude: Muscle soreness not reduced (95% CI −0.91 to 0.48; p = 0.54); the injury-marker difference was significant (95% CI −76.19 to −33.11), with no point estimate given in the abstract (Luo et al., 2026).

Inflammatory Bowel Disease Response ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A meta-analysis by Singh et al. of mostly observational studies reported high response rates in ulcerative colitis and Crohn’s disease, but randomized trials in ulcerative colitis conflicted. This bears on gut inflammation. Net: controlled evidence does not yet support benefit.

Magnitude: Response 83.2% in ulcerative colitis and 81.9% in Crohn’s disease, pooled largely from single-arm studies, no control group (Singh et al., 2021).

Decompression Sickness and Gas Embolism ⭕️ Not Central to Health & Longevity

Recompression with oxygen is standard care for decompression sickness and gas embolism (vessel-blocking bubbles), both covered by Medicare. A Cochrane review by Bennett found no randomized trial of recompression itself, so support rests on physiology and clinical experience. This bears on diving and procedural accidents, not aging.

Magnitude: Not quantified in available studies. No randomized or comparative study has measured recompression against no recompression (Bennett et al., 2012).

Chronic Refractory Osteomyelitis ⭕️ Not Central to Health & Longevity

For persistent bone infection resisting antibiotics and surgery (refractory osteomyelitis), covered by Medicare, a systematic review by Savvidou of 45 mostly uncontrolled cohort studies and case reports (460 patients) reported frequent success without relapse. The evidence is largely uncontrolled. This bears on infection care, not aging.

Magnitude: Successful outcome without relapse in 73.5% of 419 patients with complete data; no control group (Savvidou et al., 2018).

Thermal Burn Healing ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

For thermal burns, a Cochrane review by Villanueva found two poor-quality randomized trials: one reported faster healing, the other no difference in hospital stay, mortality or number of surgeries. This bears on burn care, not aging. Net: the evidence neither supports nor refutes a benefit.

Magnitude: Mean healing time 19.7 days with hyperbaric oxygen versus 43.8 days without in one trial; the trials were not pooled (Villanueva et al., 2004).

Severe Anemia When Transfusion Is Impossible ⭕️ Not Central to Health & Longevity

When transfusion is impossible, oxygen dissolved under pressure can sustain tissues in severe anemia (very low red blood cell levels). A systematic review by Van Meter of 35 publications, mostly case reports, found uniformly positive results. This bears on emergency care, not aging.

Magnitude: Not quantified in available studies. Only case reports and uncontrolled case series exist, with no comparison group (Van Meter, 2005).

Refractory Actinomycosis ⭕️ Not Central to Health & Longevity

For actinomycosis (a slow bacterial infection forming abscesses) that resists antibiotics and surgery, covered by Medicare, support comes from case reports (Manheim et al., 1969; Shauly et al., 1993). No controlled study exists. This bears on infection care, not aging.

Magnitude: Not quantified in available studies. Only case reports exist, with no comparison group (Shauly et al., 1993).

Acute Peripheral Arterial Insufficiency ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

For acute peripheral arterial insufficiency (sudden loss of limb blood flow), covered by Medicare, evidence is indirect, from chronically blocked leg arteries: Takagi’s retrospective series linked sessions to fewer amputations, but an RCT by Santema found no limb-salvage benefit. This bears on limb salvage. Net: randomized evidence shows no benefit.

Magnitude: Major amputation odds ratio 0.04 (95% CI 0.004–0.32) with hyperbaric oxygen in chronic limb-threatening ischemia (long-standing severe leg artery blockage), versus partly historical controls (Takagi et al., 2024); limb salvage 53 of 60 with hyperbaric oxygen versus 47 of 60 with standard care in diabetic patients with leg ischemia, risk difference 10% (95% CI −4 to 23) (Santema et al., 2018).

Speculative 🟨

Cellular and Tissue Aging Markers

Shamir studies reported longer immune-cell telomeres, fewer senescent cells (Hachmo et al., 2020), gene-expression shifts (Hadanny et al., 2021) and, versus a no-treatment period, denser skin collagen (Hachmo et al., 2021). Basis: unvalidated biomarkers only.

Stem Cell Mobilization and Blood Vessel Growth

Sessions raised circulating CD34+ progenitor cells in humans (Thom et al., 2006). Whether this produces lasting tissue repair in healthy adults is untested; the basis is biomarker and mechanistic data only.

Cyanide Poisoning ⭕️ Not Central to Health & Longevity

Medicare covers cyanide poisoning, yet support is animal-only: in rats, hyperbaric oxygen lowered brain lactate after cyanide exposure (Polzik et al., 2017). Basis: mechanistic and animal data. This bears on poisoning care.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has identified gene variants that predict benefit from hyperbaric oxygen; no pharmacogenetic or genetic testing is used to select candidates.
  • Baseline biomarkers: Poorer baseline sleep scores predicted larger sleep gains (Doenyas-Barak et al., 2026); Shamir trials target brain regions with low blood flow but intact tissue, assuming these respond best (Efrati et al., 2013).
  • Sex: HOT-LoCO reported a notable sex difference in response (Kjellberg et al., 2025); the Shamir sleep cohort was only 31% female (Doenyas-Barak et al., 2026), limiting conclusions for women.
  • Pre-existing conditions: In diabetic ulcers with limb ischemia (poor arterial blood supply), the DAMO₂CLES trial found no benefit (Santema et al., 2018); concussion, long COVID and PTSD benefits come largely from one group.
  • Age: Hearing gains were larger in patients younger than 50 (Topuz et al., 2004; Tong et al., 2021), while cognitive and aerobic gains were reported in adults over 64 (Hadanny et al., 2020; Hadanny et al., 2024).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Middle Ear Barotrauma ⚠️ Conflicted

Pressure changes can injure the eardrum and middle ear when the Eustachian tube (ear-to-throat pressure channel) fails to equalize, causing pain, fluid or rupture. A Cochrane review by Lin found far more barotrauma than in unpressurized controls but no excess versus sham pressurization; a systematic review of ear complications by Voigt found them in 15% of treated patients, and a cohort from Hadanny (Israel) identified it as the commonest complication. Net: pressure itself, not oxygen, causes it, so any chamber carries this risk.

Magnitude: RR 9.08 (95% CI 2.21–37.26) versus no pressurization and RR 1.07 (95% CI 0.52–2.21) versus sham pressurization (Lin et al., 2023); ear complications in 15% of 18,284 patients, no control group (Voigt et al., 2025).

Reversible Myopia and Reduced Visual Acuity

Repeated sessions shift the lens toward myopia (nearsightedness), blurring distance vision; this is usually reversible after the course stops (Camporesi, 2014). A Cochrane review by Lin rated the increased risk of reduced visual acuity high-certainty, and the UK HOT2 trial by Glover found refractive changes (shifts in the eye’s focusing power) more often than with sham.

Magnitude: Reduced visual acuity RR 4.03 (95% CI 1.65–9.84) versus no hyperbaric oxygen (Lin et al., 2023); refractive change in 30% with hyperbaric oxygen versus 11% with sham (Glover et al., 2016).

Medium 🟥 🟥

Sinus Barotrauma

Pressure changes can injure the air-filled sinuses around the nose when their openings are blocked, causing facial pain or nosebleeds (sinus squeeze). In a randomized, sham-controlled trial at 2.4 atmospheres in 50 service members with brain injury, sinus squeeze occurred only in the hyperbaric oxygen arm (Wolf et al., 2012). A multiplace-chamber (multi-person chamber) series found that 95% of symptomatic barotrauma affected the ears rather than the sinuses (Fitzpatrick et al., 1999).

Magnitude: Sinus squeeze in 0.27% of hyperbaric oxygen exposures versus 0.0% of sham exposures (Wolf et al., 2012).

Pulmonary Oxygen Toxicity ⚠️ Conflicted

Prolonged breathing of high-pressure oxygen can injure lung tissue and reduce lung function. A Cochrane review by Bennett found significant pulmonary impairment in 13% of treated patients versus none of controls in two randomized trials of acute traumatic brain injury. Earlier small studies found mild declines in small-airway function, but 88 patients, almost all without lung disease, showed no decline after 60 sessions at 2 atmospheres (Hadanny et al., 2019). Net: lung harm is documented in critically ill patients but was not seen after standard elective courses.

Magnitude: Significant pulmonary impairment in 13% with hyperbaric oxygen versus 0% without in two randomized trials (Bennett et al., 2012); after 60 sessions, no significant change in forced expiratory volume in one second, with forced vital capacity rising 0.1 L, no control group (Hadanny et al., 2019).

Confinement Anxiety and Other Session Reactions

Being enclosed in the chamber can provoke confinement anxiety (claustrophobia), which occasionally requires sedation (Camporesi, 2014). In one randomized trial within a Cochrane review by Bennett, claustrophobia affected 15% of patients treated in one-person chambers, far more often than in controls without chamber sessions. In 2,334 patients at the Shamir center, anxiety reactions, dizziness, breathlessness and chest pain each affected 0.5–1.5% (Hadanny et al., 2016).

Magnitude: Claustrophobia requiring cessation of sessions in 15 of 103 patients (15%) in one-person chambers versus none of 105 controls, RR 31.6 (95% CI 1.92–521) in one trial (Bennett et al., 2015); any adverse event in 17.4% of patients (0.72% of sessions), no control group (Hadanny et al., 2016).

Oxygen-Toxicity Seizures

High-pressure oxygen can trigger generalized seizures. A Cochrane review by Bennett of randomized trials found more oxygen-toxicity seizures with hyperbaric oxygen than without it; the gap is that these were cancer patients breathing oxygen during radiotherapy in older trials whose protocols differ from current elective courses. Across 62,614 sessions at the Shamir center, seizures were rare and only one was clearly oxygen-induced; uncontrolled epilepsy remained a contraindication (Hadanny et al., 2016).

Magnitude: Oxygen-toxicity seizures RR 6.76 (CI 1.16–39.31) versus radiotherapy without hyperbaric oxygen, pooled across cancer types, moderate-quality evidence (Bennett et al., 2018); in elective practice, seizures in 0.011% of sessions (1 in 8,945), clearly oxygen-induced in 1 in 62,614; no control group (Hadanny et al., 2016).

Low 🟥

Nuclear Cataract With Prolonged Courses

After 150 or more sessions, 7 of 15 patients with clear lenses developed nuclear cataract (clouding of the lens core) (Palmquist et al., 1984). One case followed a standard 48-session course (Gesell & Trott, 2007).

Magnitude: Nuclear cataract in 7 of 15 previously clear lenses after 150 or more sessions; no control group (Palmquist et al., 1984).

Hypoglycemia in Diabetes

Blood glucose often falls during sessions in people with diabetes. Hypoglycemia (low blood sugar) was uncommon, rarely severe and more frequent in type 1 diabetes (Stevens et al., 2015; Heyboer et al., 2019).

Magnitude: Hypoglycemia (70 mg/dL or lower) in 1.5% of 3,136 sessions; no control group (Stevens et al., 2015).

Pulmonary Edema in Heart Failure

Pulmonary edema (fluid in the lungs) has occurred with sessions in people with reduced heart pumping function, including one death (Weaver & Churchill, 2001). In a heart-failure cohort, 2 of 23 patients developed it (Schiavo et al., 2024).

Magnitude: Pulmonary edema in 2 of 23 patients with heart failure; no control group (Schiavo et al., 2024).

Pulmonary Barotrauma and Lung Collapse

Pressure changes can rupture lung air spaces, causing pneumothorax (collapsed lung) or air bubbles reaching brain arteries. A review by Brenna et al., 2022 found it occurs mainly with known lung disease; a case report described stroke-like arterial gas embolism during decompression (Ramchandani et al., 2026).

Magnitude: Pneumothorax in 0.0059% of sessions (0.15% of patients); no control group (Türkmen et al., 2025).

Chamber Fire and Equipment Failure

Oxygen-enriched chambers can ignite, with fatal results. Soft-sided and “mild” chambers that do not meet pressure-vessel and fire-safety standards add risks of fire, barotrauma, suffocation and structural failure (Murray, 2026).

Magnitude: Not quantified in available studies. The evidence consists of adverse-event reports and a narrative review, with no denominator of sessions.

Speculative 🟨

Oxidative DNA Damage

A single session at 2.5 atmospheres increased DNA strand breaks in white blood cells, without lasting oxidative lesions or mutations (Dennog et al., 1999). Long-term consequences are unknown; the basis is biomarker data only.

Cancer Growth Promotion

Concern that oxygen could feed tumors rests on mechanism. Reviews of mostly animal and observational data found no evidence of promoted growth or recurrence (Moen & Stuhr, 2012).

Risk-Modifying Factors

  • Genetic polymorphisms: Glutathione S-transferase genotypes (enzymes that neutralize reactive molecules) did not change the DNA effects of a session (Dennog et al., 1999); no other genetic risk modifiers are known.
  • Baseline biomarkers: A pre-session glucose of 150 mg/dL best separated patients who later became hypoglycemic (Stevens et al., 2015); reduced left-ventricular ejection fraction (share of blood pumped per beat) marks pulmonary-edema risk (Weaver & Churchill, 2001).
  • Sex: Women had more middle ear barotrauma in a large cohort (Hadanny et al., 2016) and in pooled data (Voigt et al., 2025).
  • Pre-existing conditions: Head and neck disease, sensory neuropathy (nerve damage that dulls sensation) and prior ear-equalizing difficulty raise barotrauma risk (Voigt et al., 2025); type 1 diabetes raises hypoglycemia risk (Stevens et al., 2015); heart failure raises pulmonary-edema risk.
  • Age: Increasing age raised barotrauma risk in pooled data (Voigt et al., 2025); children under 16 were also at higher risk (Hadanny et al., 2016). Older adults more often carry heart failure and lens changes.

Key Interactions & Contraindications

Prescription medications

  • Insulin and sulfonylureas (drugs that make the pancreas release insulin; glipizide, glyburide): Glucose fell in 75.4% of diabetic sessions, with low readings mostly in insulin users (Heyboer et al., 2019); pre- and post-session glucose checks and a pre-session meal mitigate hypoglycemia.
  • Bleomycin (prior chemotherapy): Oxygen and bleomycin can each injure lungs, but 15 previously treated patients showed no pulmonary deterioration under a graded protocol (Torp et al., 2012); baseline spirometry (a breathing test) and slow escalation are used.
  • Doxorubicin and cisplatin: Avoid during active treatment (theoretical). Animal data suggest added heart (doxorubicin) or kidney (cisplatin) toxicity; sessions are scheduled apart from chemotherapy cycles.
  • Carboplatin (platinum chemotherapy drug): In six glioma patients treated during sessions at 2 atmospheres, longer carboplatin residence time accompanied tumor response, suggesting prolonged drug exposure, though no session-free comparison was made (Suzuki et al., 2009); sessions are timed with the oncology team.
  • Disulfiram: Avoid (theoretical). It inhibits superoxide dismutase (an antioxidant enzyme), potentially increasing oxygen toxicity and seizure risk.
  • Mafenide acetate (topical burn cream): Avoid (theoretical). Inhibition of carbonic anhydrase (an enzyme that regulates carbon dioxide) causes carbon dioxide retention, which may raise seizure risk.
  • Seizure-threshold-lowering drugs (bupropion, tramadol, high-dose corticosteroids, i.e. anti-inflammatory hormone drugs): May add to oxygen-toxicity seizure risk (theoretical); stable dosing and supervised multiplace sessions mitigate it.
  • Sedatives and opioids (strong pain-relief drugs; lorazepam, oxycodone): Used for confinement anxiety, but breathing suppression raises carbon dioxide and potentially seizure risk (theoretical); lowest effective doses are used.
  • Antiplatelets and anticoagulants (drugs that reduce blood clotting; aspirin, clopidogrel, warfarin, apixaban): No interaction found; no action needed. Two cohorts found no increase in middle ear barotrauma or eardrum bleeding (Fijen et al., 2016; Howard et al., 2020); only mild nosebleeds occurred.
  • Aminoglycoside antibiotics (injectable antibiotics cleared by the kidneys; gentamicin): No interaction found; no action needed. In a randomized crossover study of five healthy men, a session did not change gentamicin half-life, clearance or peak level (Merritt & Slade, 1993).
  • Beta-blockers and calcium channel blockers (heart and blood-pressure drugs; propranolol, nifedipine): In 33 men with angina (exertional chest pain), a 1.5-atmosphere session added to propranolol’s heart-rate slowing and blunted nifedipine’s reflex heart-rate rise (Seriakov et al., 1992); heart-rate monitoring during early sessions mitigates excessive slowing.
  • Lidocaine (local anesthetic and antiarrhythmic, a heart-rhythm drug): No pharmacokinetic interaction; in two volunteers at 2.5 bar, lidocaine levels were unchanged, but marked dizziness, ear buzzing, tremor and incoordination occurred at low concentrations (Rump et al., 1999); in-chamber dosing is kept low and monitored.

Over-the-counter medications

  • Nasal decongestants (pseudoephedrine, oxymetazoline): No protective effect. RCTs found neither prevented middle ear barotrauma (Moayedi et al., 2025; Carlson et al., 1992); pseudoephedrine’s stimulant effect could lower seizure threshold (theoretical).
  • Sedating antihistamines (allergy drugs that cause drowsiness; diphenhydramine, doxylamine): Drowsiness may impair ear-equalizing maneuvers and in-chamber communication (theoretical); non-sedating alternatives avoid this.
  • Alcohol: Avoid before sessions (theoretical). Impaired coordination and dehydration complicate ear equalization and chamber safety.

Supplements

  • High-dose antioxidants (vitamin C, vitamin E, N-acetylcysteine): They could blunt oxygen-driven signaling proposed to underlie benefits (theoretical); no human hyperbaric study exists, though diving data suggest reduced vascular stress (Hoencamp et al., 2019).
  • Glucose-lowering supplements (berberine, chromium, alpha-lipoic acid): Additive with session-related glucose falls in diabetes, raising hypoglycemia risk (theoretical); glucose checks before sessions mitigate it.
  • Caffeine (coffee, caffeine supplements): No interaction found; no action needed. In two volunteers, caffeine levels and elimination were unchanged during a 110-minute session at 2.5 atmospheres (Rump et al., 1997).
  • Exogenous ketones and ketogenic diets: No action needed; possibly protective (theoretical). Animal research suggests ketosis (a fat-burning state with raised blood ketones) delays oxygen-toxicity seizures; no human hyperbaric data exist.

Other interventions

  • Scuba diving and air travel: Additional pressure changes add ear and sinus stress and decompression load (theoretical); spacing these from sessions mitigates it.
  • Radiotherapy: Breathing hyperbaric oxygen during radiotherapy increased severe radiation tissue reactions (RR 2.35, 95% CI 1.66–3.33) and oxygen-toxicity seizures (RR 6.76) in a Cochrane review of 19 trials (Bennett et al., 2018), offsetting improved head and neck tumor control.
  • Smoking and nicotine: Avoid (theoretical). Nicotine constricts blood vessels, counteracting oxygen delivery, and smoking materials are a chamber fire hazard; active smokers were excluded from trials (NCT02790541).

Populations who should avoid Hyperbaric Oxygen Therapy:

  • Untreated pneumothorax (collapsed lung)
  • Chest disease incompatible with pressure changes, including moderate-to-severe asthma (trial exclusion, NCT04647656)
  • Ear or sinus disease that prevents pressure equalization (trial exclusion, NCT04647656)
  • Uncontrolled epilepsy (Hadanny et al., 2016)
  • Heart failure with reduced ejection fraction that is not medically optimized (Weaver & Churchill, 2001; Schiavo et al., 2024); a Shamir trial excluded ejection fraction of 35% or less (trial exclusion, NCT05349318)
  • Uncontrolled diabetes: HbA1c (three-month average blood sugar) above 8% or fasting glucose above 200 mg/dL (trial exclusion, NCT02790541)
  • Severe emphysema or moderate-to-severe obstructive lung disease (trial exclusion, NCT02790541)
  • Active smokers (trial exclusion, NCT02790541)
  • Pregnancy (theoretical)
  • People receiving doxorubicin, cisplatin or disulfiram (theoretical)

Risk Mitigation Strategies

Doses, pressures and timings below follow common practice unless cited.

  • Ear-equalization training before the first session: Experience with effective equalization was the main protective factor against middle ear barotrauma (Voigt et al., 2025); slow first compressions and pausing at ear pain prevent eardrum injury.
  • No reliance on decongestants: Pre-session decongestants did not prevent barotrauma in RCTs (Moayedi et al., 2025); tympanostomy tubes (small eardrum vents) address repeated equalization failure (Camporesi, 2014).
  • Postponing sessions during colds or sinus congestion: Blocked Eustachian tubes cannot equalize, so postponement prevents ear and sinus barotrauma.
  • Air breaks during oxygen breathing: Five-minute air breaks every 20 minutes, as in the Shamir protocol (Hadanny et al., 2020), limit continuous oxygen exposure and oxygen-toxicity seizure risk.
  • Glucose checks in diabetes: Glucose is measured before and after sessions; one program gave glucose when pre-session values were below 120 mg/dL (Heyboer et al., 2019), preventing hypoglycemia.
  • Eye examinations: Refraction before and after a course detects myopic shift; lens examination after 150 or more sessions screens for cataract (Palmquist et al., 1984).
  • Cardiac optimization: Echocardiography (heart ultrasound) in heart disease, optimized diuretics (drugs that remove excess fluid through urine) and fluid restriction allowed heart-failure patients to complete courses (Schiavo et al., 2024), reducing pulmonary-edema risk.
  • Code-compliant hard-shell chambers: Facilities meeting pressure-vessel and fire standards, cotton clothing and no flammable cosmetics reduce fire and equipment-failure risk (Murray, 2026).
  • Seizure screening and response: Excluding uncontrolled epilepsy (Hadanny et al., 2016) and switching to air during any seizure limit oxygen-toxicity harm.

Therapeutic Protocol

Pressures, durations and session counts are cited to their source; other parameters without a citation (timing, stepwise pressure increases, cycling) reflect common practice. Two traditions coexist: indication-limited conventional hyperbaric medicine and regeneration-oriented longevity programs.

  • Shamir and Aviv longevity protocol: 2 atmospheres absolute, 100% oxygen, 90 minutes with 5-minute air breaks every 20 minutes, 60 weekday sessions (Hadanny et al., 2020; Hadanny et al., 2024); popularized by Shai Efrati and Aviv Clinics.
  • Athletic performance protocol: 2 atmospheres absolute, 100% oxygen for 60 minutes, 40 sessions (Hadanny et al., 2022).
  • Conventional hospital protocol: About 2.4 atmospheres (240–250 kilopascals) for 80–90 minutes, 30–40 daily sessions for wounds and radiation injury (Fedorko et al., 2016; Oscarsson et al., 2019).
  • Lower-pressure neurological protocol: 1.5 atmospheres for 60 minutes, 40 sessions, used for post-concussion syndrome by Harch et al., 2020 and Boussi-Gross et al., 2013.
  • Mild soft-chamber approach: Spa and home chambers are typically designed for operating pressures of 3–5 pounds per square inch (Murray, 2026); comparable low pressures with air served as sham in trials (Miller et al., 2015).
  • Best time of day: No study has compared session timing; daytime sessions are typical, with a meal beforehand in diabetes.
  • Half-life: Oxygen has no elimination half-life in the drug sense; tissue oxygen returns toward baseline within hours after decompression, so proposed effects accumulate across repeated sessions.
  • Single versus split sessions: Once-daily sessions are standard for elective courses; twice-daily schedules are used for some clinical indications (Torp et al., 2012).
  • Genetic polymorphisms: No gene variant is known to alter pressure, duration or session count; no genetic testing guides protocol choice.
  • Sex differences: Women’s higher barotrauma risk (Voigt et al., 2025) favors slower first compressions; no sex-specific dosing exists.
  • Age considerations: Longevity trials enrolled adults over 64 (Hadanny et al., 2020); because barotrauma risk rises with age, ear assessment precedes courses in older adults.
  • Baseline biomarkers: Baseline cognitive, exercise and brain blood-flow testing defines goals; poorer baseline sleep predicted larger sleep gains (Doenyas-Barak et al., 2026).
  • Pre-existing conditions: Diabetes, heart failure, lung disease and epilepsy change session plans through glucose checks, cardiac optimization or exclusion, as detailed in the risk sections.

Discontinuation & Cycling

  • Course-based, not lifelong: Longevity protocols are a single 12-week course of 60 sessions (Hadanny et al., 2020); no trial has tested lifelong or periodic maintenance use.
  • Withdrawal effects: None reported; stopping causes no rebound, and myopic shift usually reverses after the course ends (Camporesi, 2014).
  • Tapering: Not applicable; sessions simply stop at the end of the course.
  • Durability: Follow-up in older-adult studies ranged from 1 to about 12 weeks (Mohammadi et al., 2026); concussion gains persisted at least two months (Harch et al., 2020).
  • Cycling and repeat courses: Repeat or booster courses are offered commercially but unstudied; very long cumulative exposure raises cataract risk (Palmquist et al., 1984).

Sourcing and Quality

  • A procedure, not a product: Hyperbaric oxygen is delivered in a facility, so quality depends on chamber type, oxygen delivery and supervision rather than formulation or purity.
  • Hard-shell versus soft chambers: Trial protocols used hard monoplace (one-person) or multiplace chambers; soft “mild” chambers often fail pressure-vessel and fire-safety standards and cannot reach trial pressures (Murray, 2026).
  • Accreditation: Undersea and Hyperbaric Medical Society facility accreditation signals safety standards; the society’s members earn revenue from hyperbaric treatment, a financial interest worth noting.
  • Supervision: A hyperbaric-trained physician screens for contraindications, and trained attendants manage ear problems, anxiety and seizures during sessions.
  • Providers: Hospital hyperbaric units focus on established indications; Aviv Clinics delivers the Shamir longevity protocol, and its co-founder Shai Efrati and head of research Amir Hadanny also lead the supporting research (Aviv Scientific leadership page).

Practical Considerations

  • Time to effect: Cognitive and aerobic changes were measured after 60 sessions over about three months (Hadanny et al., 2020; Hadanny et al., 2024); hearing benefit was larger when treatment started within 14 days of onset (Tong et al., 2021).
  • Time burden: Each session occupies about two hours including compression and decompression, five days a week for roughly three months.
  • Common pitfalls: Equating soft “mild” chambers with trial protocols, starting sessions while congested, assuming effects persist indefinitely, and treating unvalidated telomere tests as proof of benefit.
  • Regulatory status: Chambers are Class II devices cleared by the US Food and Drug Administration (FDA), which reported fires causing serious injuries and deaths (FDA safety letter). Medicare pays only for listed conditions, excluding senility and Alzheimer’s (Medicare coverage determination), so longevity courses are self-paid.
  • Cost and access: A 12-week Aviv program costs about $60,000, with prices starting at $20,000, and is not covered by insurance (Florida Trend, 2025).
  • Payer and seller incentives: Payers limiting coverage of an expensive procedure, and clinics selling programs, each have systematic financial incentives that can bias guidelines, coverage decisions and research funding.

Interaction with Foundational Habits

  • Sleep: Potentiating, uncontrolled evidence. In 395 patients, 60 sessions were associated with better Pittsburgh Sleep Quality Index scores, largest in poor sleepers (Doenyas-Barak et al., 2026); improved brain blood flow is the proposed mechanism. Sessions are typically scheduled in daytime.
  • Nutrition: Indirect. People with diabetes eat before sessions to prevent glucose falls (Heyboer et al., 2019); ketogenic diets are hypothesized to protect against oxygen-toxicity seizures, and high-dose antioxidants could blunt oxygen signaling (theoretical). No nutrient depletion is documented.
  • Exercise: Potentiating. Trials reported higher VO₂max in older adults and athletes (Hadanny et al., 2024; Hadanny et al., 2022), proposed to stem from better heart-muscle blood flow and mitochondrial function; Aviv programs pair sessions with training. Muscle-injury markers recovered faster after strenuous exercise, but soreness did not (Luo et al., 2026).
  • Stress management: Direct for trauma-related distress: PTSD symptoms fell versus sham, alongside improved brain-network connectivity on imaging, the proposed mechanism (Doenyas-Barak et al., 2024). Confinement can itself provoke anxiety (Hadanny et al., 2016); breathing techniques and chamber orientation help. Effects on cortisol are unstudied.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes fitness for pressure and the outcomes the course aims to change: an ear examination with otoscopy (viewing the eardrum), chest assessment with spirometry when lung disease is present, an eye refraction check, glucose and HbA1c in diabetes, echocardiography in heart disease, and baseline cognitive, sleep and exercise testing to define success.

Ongoing monitoring follows a fixed cadence: ear checks after the first three sessions and whenever pain occurs; glucose before and after every session in diabetes; refraction at course end (about 12 weeks) and a lens examination if sessions exceed 150; and repeat cognitive, sleep and exercise testing at course end and again 3–6 months later to judge durability.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Pre-session capillary glucose (diabetes) Above 120 mg/dL before each session (Heyboer et al. protocol) Safety: prevents hypoglycemia Heyboer et al., 2019; conventional fasting reference range 70–99 mg/dL; type 1 diabetes carries higher risk
HbA1c Below 8% for trial eligibility (Shamir trial exclusion criterion) Safety: uncontrolled diabetes excluded HbA1c = glycated hemoglobin, a three-month glucose average; NCT02790541; conventional reference range 4.0–5.6%; no fasting needed
Refraction and visual acuity No established target; track change from own baseline Safety: detects myopic shift and cataract Lin et al., 2023; lens examination after 150 or more sessions (Palmquist et al., 1984)
Eardrum appearance (otoscopy) No established target; track Teed grade change from baseline Safety: barotrauma pauses or changes sessions Teed scale grades eardrum injury 0–5 (Carlson et al., 1992); check after early sessions
Spirometry (FEV1, FVC) FEV1, FVC and FEV1/FVC at or above the lower limit of normal for age, sex and height (standard reference range) Safety: lung disease or oxygen toxicity FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; no decline after 60 sessions (Hadanny et al., 2019)
Left-ventricular ejection fraction 52–72% in men, 54–74% in women (standard reference range) Safety: low values flag pulmonary-edema risk Echocardiography in heart disease (Weaver & Churchill, 2001)
VO₂max (cardiopulmonary exercise test) No established target; track change from own baseline Expected to change: aerobic capacity Rose 1.91 mL/kg/min in the Shamir trial (Hadanny et al., 2024); same test protocol each time
Global cognitive score (computerized battery) No established target; track change from own baseline Expected to change: cognition Hadanny et al., 2020; sham trial found similar gains (NCT03036254); same battery and time of day
Pittsburgh Sleep Quality Index 5 or lower, the cutoff for undisturbed sleep used by Doenyas-Barak et al. Expected to change: sleep quality Questionnaire, not a laboratory test; no conventional reference range (Doenyas-Barak et al., 2026)

Qualitative markers:

  • Ear comfort and ease of equalization across sessions
  • Distance-vision clarity
  • Energy and fatigue levels
  • Sleep quality and morning alertness
  • Mental clarity, attention and word-finding
  • Exercise tolerance and recovery
  • Anxiety during chamber sessions

Emerging Research

  • Prodromal (early, mild-symptom stage) Alzheimer’s disease with cerebrovascular disease (disease of the brain’s blood vessels) (NCT05349318): Shamir sham-controlled RCT, 100 participants planned, computerized cognition endpoint. Estimated completion (March 2025) has passed; status unknown, no results posted. A positive result would strengthen the cognitive item; a null result would weaken it further.
  • Post-COVID cognition (NCT04647656): Shamir double-blind sham-controlled RCT, 91 participants planned, cognition endpoint, recruiting, completion 2027. A positive result would replicate the 2022 benefit; a null result would push the long COVID item toward Low.
  • Post-stroke depression (NCT07423273): Shamir sham-controlled RCT, 142 participants planned, depression-symptom endpoint, completion 2030. A positive result would extend mental-health benefits; a null result would weaken mood claims.
  • Circulating stem cells (NCT06748586): Single-arm Shamir study of 60 participants measuring blood-forming stem cells, completion 2027. A positive result would add biomarker support for the mechanism; a null result would undercut it; neither tests clinical outcomes.
  • VO₂max at 1.75 atmospheres (NCT07361861): University of Texas at Austin single-arm study of 30 healthy adults aged 30–60; estimated completion (July 2026) has passed while the registry still lists recruiting, no results posted. A positive result would be the first non-Shamir aerobic signal; a null result would weaken that item.
  • Completed sham-controlled cognition trial (NCT03036254): Mount Sinai trial of 155 older adults with type 2 diabetes, completed 2024, results posted showing similar cognitive gains with sham; a full peer-reviewed report could clarify expectation effects.
  • Independent replication and durability: A 2026 systematic review found follow-up of 12 weeks at most in older adults (Mohammadi et al., 2026); a methodological guide by authors partly affiliated with a commercial longevity company urges multicenter, sham-controlled designs (Simayijiang et al., 2026).
  • Mild chambers: No controlled trial has tested 1.3-atmosphere soft chambers for aging outcomes; their safety and regulatory gaps are documented (Murray, 2026), making them a priority for evaluation.

Conclusion

Hyperbaric oxygen therapy means breathing pure oxygen in a pressurized chamber, delivered as a course of dozens of near-daily sessions. Its best-supported uses are medical: helping some non-healing diabetic wounds and radiation-damaged tissue heal, and improving hearing recovery after sudden hearing loss, although several careful trials in these areas found no benefit.

For people pursuing longevity, the central claims are sharper thinking, greater aerobic fitness and slower cellular aging in healthy older adults. Thinking gains appear in trials where participants knew their treatment and in combined analyses of studies in people with dementia, but the one trial that used simulated pressurization found similar gains without the oxygen, so expectation and attention may explain part of the effect. Fitness gains come from a single research group, and the cellular aging findings rest on small blood and skin studies, mostly without a separate comparison group.

Most longevity research comes from one Israeli center whose director co-founded, and whose head of research helps lead, the commercial clinic network that sells the protocol, a clear financial conflict of interest; insurers, for their part, have reasons to limit coverage of an expensive treatment. Harms are usually mild and reversible, with ear pressure injury and temporary nearsightedness most common, while seizures, lung collapse, fluid on the lungs, cataract after very long courses and chamber fires are rare but serious. Overall, the evidence for healthy-aging benefits is early, concentrated in one group and short-term, set against high cost and a large time commitment.

Top - Benefits - Risks - Protocol